Universal nirsevimab prophylaxis is linked to fewer respiratory syncytial virus cases and milder disease in infants, real-world evidence from Italy shows.
Universal infant nirsevimab prophylaxis significantly reduced RSV-related hospitalisations and outpatient visits across two seasons in Spain.
Conditions in Gaza’s displacement camps, malnutrition, and Israeli bans on the entry of medicines increase the risk.
AIM: The “2026 Guideline for the Early Management of Patients With AIS” replaces the “2018 Guidelines for the Early Management of Patients With AIS” and the 2019 update to reflect recent advances in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results